blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4313308

EP4313308 - TEAD INHIBITORS AND USES THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  05.01.2024
Database last updated on 19.10.2024
FormerThe international publication has been made
Status updated on  30.09.2022
Formerunknown
Status updated on  25.04.2022
Most recent event   Tooltip31.05.2024Change: Validation statespublished on 03.07.2024  [2024/27]
31.05.2024Change - extension statespublished on 03.07.2024  [2024/27]
Applicant(s)For all designated states
Cedilla Therapeutics, Inc.
245 First Street, 3rd Floor
Cambridge, MA 02142 / US
[2024/06]
Inventor(s)01 / RENNIE, Glen Robert
Cambridge, Massachusetts 02142 / US
02 / SCHWARTZ, C. Eric
Cambridge, Massachusetts 02142 / US
03 / KIRMAN, Louise
Cambridge, Massachusetts 02142 / US
04 / PORTER, Dale
Cambridge, Massachusetts 02142 / US
05 / SONG, Ling
Cambridge, Massachusetts 02142 / US
 [2024/06]
Representative(s)Tostmann, Holger Carl
Wallinger Ricker Schlotter Tostmann
Patent- und Rechtsanwälte Partnerschaft mbB
Zweibrückenstrasse 5-7
80331 München / DE
[2024/06]
Application number, filing date22716705.325.03.2022
[2024/06]
WO2022US21842
Priority number, dateUS202163166769P26.03.2021         Original published format: US 202163166769 P
US202163226972P29.07.2021         Original published format: US 202163226972 P
US202163292367P21.12.2021         Original published format: US 202163292367 P
[2024/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022204452
Date:29.09.2022
Language:EN
[2022/39]
Type: A1 Application with search report 
No.:EP4313308
Date:07.02.2024
Language:EN
The application published by WIPO in one of the EPO official languages on 29.09.2022 takes the place of the publication of the European patent application.
[2024/06]
Search report(s)International search report - published on:EP29.09.2022
ClassificationIPC:A61P35/00, C07D215/38, C07D215/48, C07D217/02, C07D217/06, C07D239/74, C07D239/94, C07D241/42, C07D471/04, C07D471/14, C07D487/04, C07D519/00, A61K31/498, A61K31/4985, A61K31/472, A61K31/517, A61K31/47, A61K31/519, A61K31/437, A61K31/404, A61K31/52
[2024/06]
CPC:
C07D471/04 (EP,US); C07D487/04 (EP,US); A61P35/00 (EP);
C07D215/14 (US); C07D215/233 (US); C07D215/38 (EP);
C07D215/48 (EP); C07D217/02 (EP); C07D217/06 (EP);
C07D239/74 (EP,US); C07D239/94 (EP); C07D241/42 (EP);
C07D401/04 (US); C07D401/12 (US); C07D405/04 (US);
C07D471/14 (EP,US); C07D519/00 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/06]
TitleGerman:TEAD-HEMMER UND VERWENDUNGEN DAVON[2024/06]
English:TEAD INHIBITORS AND USES THEREOF[2024/06]
French:INHIBITEURS DE TEAD ET LEURS UTILISATIONS[2024/06]
Entry into regional phase23.10.2023National basic fee paid 
23.10.2023Designation fee(s) paid 
23.10.2023Examination fee paid 
Examination procedure24.10.2023Examination requested  [2024/06]
24.10.2023Date on which the examining division has become responsible
22.05.2024Amendment by applicant (claims and/or description)
Fees paidRenewal fee
27.03.2024Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XAI]WO2009029375  (LEAD THERAPEUTICS INC [US], et al) [X] 1,2,6,10,12,13,21-24,28 * compounds 56-60, 72-86 * * claims 1, 27, 31 * [A] 5,7-9,11,14-20,25-27 [I] 29-35;
 [XAI]WO2014015523  (HUTCHISON MEDIPHARMA LTD [CN], et al) [X] 1,2,5-7,9-11,14,15,17-19,21-26,28 * Several intermediates, eg 1c, 6c, 7c, 8d, 8e, 8f, 8g, 9b, etc * * Numerous exemplified compounds, eg compound 1, 2, 3, etc, 180, etc * * claims 1, 13, 16, 17 * [A] 8,12,13,16,20,27 [I] 29-35;
 [XAI]WO2014076237  (BOEHRINGER INGELHEIM INT [DE]) [X] 1,2,5-7,9,10,15,17,19,21-25,28 * Numerous exemplified compounds, eg I-1, I-2, etc, II-1, etc * * Compounds K-1 to K-6, M-1 to M-6, etc * * claims 1, 16, 17 * [A] 8,11-14,16,18,20,26,27 [I] 29-35;
 [XAI]WO2015073528  (PROTEOSTASIS THERAPEUTICS INC [US]) [X] 1,2,5-8,10,11,14,15,19-25,28 * Numerous active compounds, eg 116, 141, 144, 196 * * Numerous synthetic intermediates, eg compounds LVII, LVIII, LIX * * claims 1, 79, 92 * [A] 9,12,13,16-18,26,27 [I] 29-35;
 [XA]RU2572076  (FEDERAL NOE G BJUDZHETNOE NAUCHNOE UCHREZHDENIE NII FARMAKOLOGII IM V V ZAKUSOVA [RU]) [X] 1,2,5-7,10,11,20-26,28 * 1-phenylpyrollo[1,2-a]pyrazine-3-carboxylic acid and its methyl ester; page 14, line 32 - line 36 * * The eleven exemplified compounds * [A] 8,9,12-19,27,29-35;
 [A]WO2017064277  (INVENTIVA [FR]) [A] 1,2,5-35 * Many examples, eg Example 11, 12, 21, 39 etc * * claims 1, 12 *;
 [XAI]WO2020140052  (SPV THERAPEUTICS INC [US]) [X] 1,2,5,6,10,16,21-24,28 * Numerous compounds * * claims 1, 12, 13 * [A] 7-9,11-15,17-20,25-27 [I] 29-35;
 [XAI]WO2020154350  (THERAVANCE BIOPHARMA R&D IP LLC [US]) [X] 1,2,5,6,11,14,17,21-25,28 * Several exemplified compounds, eg Examples 1, 5, 6 etc * * Several synthetic intermediates * * claims 1, 17 * * page 34, line 7 - line 21 * [A] 7-10,12,13,15,16,18-20,26,27 [I] 29-35;
 [XA]RU2734240  (FEDERALNOE GOSUDARSTVENNOE BYUDZHETNOE NAUCHNOE UCHREZHDENIE NAUCHNO ISSLEDOVATELSKIJ INST FARMAKOLO [RU]) [X] 1,2,5-7,10,11,20-26,28 * 1-Phenylpyrollo[1,2-a]pyrazine-3-carboxylic acid; page 5, line 19 - line 20 * * The five exemplified compounds * [A] 8,9,12-19,27,29-35;
 [XPA]WO2021081211  (ACCENT THERAPEUTICS INC [US]) [XP] 1 * the whole document *[A] 2,5-35;
 [XI]  - VERENA B K KUNIG ET AL, "TEAD-YAP Interaction Inhibitors and MDM2 Binders from DNA-Encoded Indole-Focused Ugi Peptidomimetics", ANGEWANDTE CHEMIE, WILEY - V C H VERLAG GMBH & CO. KGAA, DE, (20200715), vol. 132, no. 46, doi:10.1002/ANGE.202006280, ISSN 0044-8249, pages 20518 - 20522, XP071382995 [X] 1,2,5,6,9,19,21-25,28-33 * compounds 8-15 * * Biological activity teachings of said compounds throughout the document * [I] 7,8,10-18,20,26,27,34,35

DOI:   http://dx.doi.org/10.1002/ange.202006280
 [XAI]  - SARAH A. SMITH ET AL, "TEAD-YAP Interaction Inhibitors and MDM2 Binders from DNA-Encoded Indole-Focused Ugi Peptidomimetics", JOURNAL OF MEDICINAL CHEMISTRY, US, (20190114), vol. 62, no. 3, doi:10.1021/acs.jmedchem.8b01402, ISSN 0022-2623, pages 1291 - 1305, XP055623783 [X] 1,2,6,9,18,19,21-24,28-32 * compound 8 * * Biological activity teachings of said compound throughout the document * [A] 5,7,8,10-17,20,25-27 [I] 33-35

DOI:   http://dx.doi.org/10.1021/acs.jmedchem.8b01402
 [XAI]  - FLORIANE GIBAULT ET AL, "Toward the Discovery of a Novel Class of YAP?TEAD Interaction Inhibitors by Virtual Screening Approach Targeting YAP?TEAD Protein?Protein Interface", CANCERS, (20180508), vol. 10, no. 5, doi:10.3390/cancers10050140, page 140, XP055561246 [X] 1,2,6,10,14,15,18,20-24,28-32 * Hit 4 * * Biological activity teachings of said compound throughout the document * [A] 5,7-9,11-13,16,17,19,25-27 [I] 33-35

DOI:   http://dx.doi.org/10.3390/cancers10050140
 [XA]  - MOKROV G V ET AL, "Design, synthesis and anxiolytic-like activity of 1-arylpyrrolo[1,2-a]pyrazine-3-carboxamides", BIOORGANIC, ELSEVIER, AMSTERDAM, NL, (20150423), vol. 23, no. 13, doi:10.1016/J.BMC.2015.04.049, ISSN 0968-0896, pages 3368 - 3378, XP029170432 [X] 1,2,5-7,9-11,20-26,28 * Scheme 6; page 3372; compounds 15, 16a, 16b * * figure 2; compounds CB-34, FGIN-1-27, A, YL-IPAD08 * * Scheme 5 and Scheme 6;; compound 1a to 1h * [A] 8,12-19,27,29-35

DOI:   http://dx.doi.org/10.1016/j.bmc.2015.04.049
 [XA]  - BLACK D S, "PRODUCT CLASS 13: 1H-PYRROLES", SCIENCE OF SYNTHESIS, THIEME VERLAG, STUTTGART, DE, (20020101), vol. 9, pages 441 - 552, XP001199769 [X] 1,2,5-7,10,14,21-26 * compounds 197, 444, 562 * [A] 8,9,11-13,15-20,27-35
 [A]  - POBBATI AJAYBABU V. ET AL, "Identification of Quinolinols as Activators of TEAD-Dependent Transcription", ACS CHEMICAL BIOLOGY, vol. 14, no. 12, doi:10.1021/acschembio.9b00786, ISSN 1554-8929, (20191220), pages 2909 - 2921, URL: http://pubs.acs.org/doi/pdf/10.1021/acschembio.9b00786, XP055919078 [A] 1,2,5-35 * the whole document *

DOI:   http://dx.doi.org/10.1021/acschembio.9b00786
by applicantWO2019113236
    - S. M. BERGE et al., "pharmaceutically acceptable salts", J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19
    - YU et al., Cell, (20120000), vol. 150, pages 780 - 791
    - ZHAO et al., Genes & Dev., (20110000), vol. 25, pages 51 - 63
    - "UniProt", Database accession no. P28347-1
    - "UniProtKB", Database accession no. Q15561
    - HOLDEN et al., Cancers, (20180000), vol. 10, no. 81, pages 1 - 15
    - CHAN et al., Nature Chem. Biol., (20160000), vol. 12, pages 282 - 289
    - NOLAND et al., Structure, (20160000), vol. 24, pages 1 - 8
    - GIBAULT et al., J. Med. Chem., (20180000), vol. 61, pages 5057 - 5072
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.